2025/08/06
2024/08/06
2024/05/21
2021/10/31
Generation of a Transgenic Zebrafish Line for In Vivo Assessment of Hepatic Apoptosis
2021/08/19
2021/07/09
Establishment of a Quality Control Protocol for Zebrafish Developmental Toxicity Studies
2020/10/13
2020/05/28
A novel orexin antagonist from a natural plant was discovered using zebrafish behavioural analysis
2019/10/15
C3orf70 Is Involved in Neural and Neurobehavioral Development
2019/09/22
2025/08/06
Kanako Mori, Yoshinobu Aoki, Mai Hayashi, Wataru Sugimoto, Mizuho Ono, Saaya Umekita, Tatsuhiro Niino, Tomonori Ebata, Fumito Mikashima, Kazushige Maki, Toshio Tanaka, Hiromi Hirata, Hajime Kojima
J Toxicol Sci. 2025;50(8):431-444. doi: 10.2131/jts.50.431.
Abstract
Exposure of embryos or fetuses to harmful substances, such as teratogens, can result in embryonic or fetal death and a wide range of malformations. Zebrafish models have emerged as a valuable tool for assessing developmental toxicity and safety profiles of chemical compounds. Our previous research demonstrated that zebrafish larvae exhibit developmental abnormalities that mirror those observed in mammalian studies for more than 80% of the known Reference Compounds listed in the ICH S5 (R3) guideline. In this study, we presented high-resolution images depicting pharmaceutical-induced malformations across multiple anatomical regions, including the body axis, somites, notochord, fins, head, eyes, otoliths, jaw, heart, abdomen, and whole body. Frequent co-occurrence of specific defects, such as body axis and notochord malformations, was observed as described previously. Some physiological and morphological features, including heartbeat rate alterations and swim bladder inflation, were deemed dispensable for MEFL testing in zebrafish. Reproducibility was confirmed through inter-laboratory testing conducted both within our group and by other groups, supporting the reliability of zebrafish MEFL testing as an alternative approach in line with ICH S5 (R3).